Skip to main content
. 2014 Feb;5(1):13–17. doi: 10.1177/2040620713510481

Table 2.

Response to treatment with bosutinib and imatinib in the randomized trial for first-line treatment of chronic phase chronic myeloid leukemia.

Response Bosutinib
Imatinib
% Time to response % Time to response
CCyR 70% 12.9 weeks 68% 24.6 weeks
MMR 41% 37.1 weeks 27% 72.3 weeks

CCyR, complete cytogenetic remission; MMR, major molecular remission.